Strategic Diagnostics' Antibody Revenue Gains Tempered by Ag/GMO Decline | GenomeWeb
NEW YORK (GenomeWeb News) — Strategic Diagnostics today said third-quarter revenues were flat as R&D spending rose 9 percent and profit fell around 70 percent.
Total receipts for the three months ended Sept. 30 dipped slightly to $6.56 million from $6.62 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.